Edward L. Giovannucci, D.Sc., M.D.
Co-Author
This page shows the publications co-authored by Edward Giovannucci and Massimo Loda.
Connection Strength
2.288
-
MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):201-207.
Score: 0.184
-
Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
Score: 0.167
-
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb; 106(2):djt430.
Score: 0.141
-
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
Score: 0.137
-
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
Score: 0.117
-
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
Score: 0.111
-
Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
Score: 0.098
-
Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2021 05; 30(5):1000-1008.
Score: 0.058
-
Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):751-756.
Score: 0.057
-
Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
Score: 0.053
-
Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020 05 15; 146(10):2694-2702.
Score: 0.052
-
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 12 31; 39(12):1431-1437.
Score: 0.050
-
Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):193-200.
Score: 0.046
-
Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov 01; 123(21):4130-4138.
Score: 0.045
-
Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017 May; 77(6):647-653.
Score: 0.043
-
The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22.
Score: 0.043
-
Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab. 2016 06; 101(6):2520-7.
Score: 0.041
-
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer. 2016 Apr 12; 114(8):939-44.
Score: 0.041
-
Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
Score: 0.041
-
Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016 Mar; 103(3):851-60.
Score: 0.041
-
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.040
-
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
Score: 0.040
-
MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res. 2016 Jan; 4(1):33-40.
Score: 0.040
-
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec; 75(16):1926-33.
Score: 0.039
-
Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun; 36(6):639-47.
Score: 0.038
-
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
Score: 0.038
-
5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7.
Score: 0.037
-
Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
Score: 0.036
-
SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
Score: 0.036
-
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
Score: 0.035
-
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
Score: 0.035
-
Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
Score: 0.034
-
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
Score: 0.032
-
Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):56.
Score: 0.031
-
Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
Score: 0.030
-
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103(7):1025-33.
Score: 0.028
-
Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
Score: 0.028
-
Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
Score: 0.027
-
Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
Score: 0.026
-
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
Score: 0.025
-
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26(35):5713-20.
Score: 0.025
-
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58(1):90-6.
Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.